 Research
 Open Access
Effectiveness of antiviral prophylaxis coupled with contact tracing in reducing the transmission of the influenza A (H1N12009): a systematic review
 Kenji Mizumoto^{1, 2},
 Hiroshi Nishiura^{1, 3}Email author and
 Taro Yamamoto^{2}
https://doi.org/10.1186/17424682104
© Mizumoto et al.; licensee BioMed Central Ltd. 2013
 Received: 27 November 2012
 Accepted: 14 January 2013
 Published: 16 January 2013
Abstract
Background
During the very early stage of the 2009 pandemic, mass chemoprophylaxis was implemented as part of containment measure. The purposes of the present study were to systematically review the retrospective studies that investigated the effectiveness of antiviral prophylaxis during the 2009 pandemic, and to explicitly estimate the effectiveness by employing a mathematical model.
Methods
A systematic review identified 17 articles that clearly defined the cases and identified exposed individuals based on contact tracing. Analysing a specific schooldriven outbreak, we estimated the effectiveness of antiviral prophylaxis using a renewal equation model. Other parameters, including the reproduction number and the effectiveness of antiviral treatment and school closure, were jointly estimated.
Results
Based on the systematic review, median secondary infection risks (SIRs) among exposed individuals with and without prophylaxis were estimated at 2.1% (quartile: 0, 12.2) and 16.6% (quartile: 8.4, 32.4), respectively. A very high heterogeneity in the SIR was identified with an estimated I ^{2} statistic at 71.8%. From the outbreak data in Madagascar, the effectiveness of mass chemoprophylaxis in reducing secondary transmissions was estimated to range from 92.8% to 95.4% according to different model assumptions and likelihood functions, not varying substantially as compared to other parameters.
Conclusions
Only based on the metaanalysis of retrospective studies with different study designs and exposure settings, it was not feasible to estimate the effectiveness of antiviral prophylaxis in reducing transmission. However, modelling analysis of a single outbreak successfully yielded an estimate of the effectiveness that appeared to be robust to model assumptions. Future studies should fill the data gap that has existed in observational studies and allow mathematical models to be used for the analysis of metadata.
Keywords
 Oseltamivir
 Reproduction Number
 Zanamivir
 Retrospective Observational Study
 Secondary Case
Background
In April 2009, a pandemic caused by the influenza A (H1N12009) virus (pH1N1) was recognized, spreading rapidly across the world [1]. The virulence of pH1N1 infection appeared to be likely lower than those of other pandemics during the 20th century [2], but the population impact was not negligible as a whole [3]. To strengthen preparedness against future pandemics better with plentiful supports of scientific evidence, it is fruitful to systematically review the lessons from the 2009 pandemic and explicitly analyse the epidemiological dataset [4]. In particular, the effectiveness of containment measure, including contact tracing, case isolation, antiviral prophylaxis, school closure and other radical and resourceconsuming countermeasures should be assessed by using the empirical data. This can only be achieved by experiencing an actual pandemic. The datasets from the 2009 pandemic are thus deemed the most valuable source for epidemiological investigations which include an explicit analysis using mathematical and statistical modelling techniques.
Among various public health measures, the present study focuses on the effectiveness of antiviral prophylaxis as part of the containment measure. In the very early stage of the 2009 pandemic, mass chemoprophylaxis was implemented to strictly prevent secondary transmission among close contacts of confirmed cases [5, 6]. Since the retrospective epidemiological studies of chemoprophylaxis, commonly coupled with contact tracing, took place across the world, we are granted a precious opportunity to empirically assess the effectiveness of these countermeasures in combination. To date, a number of original studies and systematic reviews have been published on the effectiveness of antiviral prophylaxis against pH1N1, including a study that analysed empirical datasets of pH1N1 in a confined household setting [7]. However, a systematic review has been only partially focused on pH1N1 [8] with a restriction to randomized controlled trials that recruited participants based on some specified definition of “contact”. The estimated effectiveness of prophylaxis derived from such studies has not been directly applicable to other population settings (e.g. not generally applicable to any other contacts) and thus to the associated policymaking. Moreover, a few original studies have rested on very rigorous contact tracing, and the finding has been specific to that particular population (e.g. military conscripts in Singapore [9–11]). Thus, again it is difficult to apply the finding to other practical settings. Similar observational studies have been hardly published.
Given that the effectiveness of chemoprophylaxis at a population level has yet to be explicitly assessed, systematically reviewing and analysing published retrospective observational studies would be a great asset to consider and plan for future contingency planning that involves antiviral prophylaxis. The objectives of the present study are two folds. First, we aim to systematically review the effectiveness of chemoprophylaxis during the course of the 2009 pandemic. Because the effectiveness of chemoprophylaxis in reducing the risk of secondary transmission cannot be separately estimated from that of contact tracing based on retrospective studies, we estimate the effectiveness of the combined two countermeasures. Second, we aim to explicitly estimate the effectiveness of chemoprophylaxis coupled with contact tracing by employing a mathematical modelling technique, focusing on a single epidemic record of a schooldriven outbreak.
Methods
The present study consists of two major analytic steps, i.e. (i) a systematic review of literature and (ii) mathematical modelling of an outbreak data. As for the former, this systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement [12].
Search strategy

#1: ‘influenza’ OR ‘flu’ OR ‘H1N1*’ OR ‘pH1N1’ OR ‘nH1N1’ OR ‘vH1N1’

#2: ‘pandemic’

#3: ‘prophylaxis’ OR ‘chemophylolaxis’

#4: ‘antiviral’ OR ‘oseltamivir’ OR ‘zanamivir’ OR ‘neuraminidase’

#5: #1 AND #2 AND #3 AND #4
The search was limited to studies published on or after 20 April 2009, i.e. subsequent to the declaration of emergence of pH1N1 through 2 October 2012.
Study selection
All titles identified by the search strategy were independently screened by two authors (K.M. and H.N.). Abstracts of potentially relevant titles were then reviewed for eligibility, and selected articles were selected for closer examination if any description of either a complete antiviral chemoprophylaxis or contact tracing was given. The duration of “complete” prophylaxis was defined as those lasting for 7 days or longer. In addition, eligible articles must define the “cases” explicitly and identify exposed individuals based on contact tracing (e.g. based on sharing household or any other opportunities of close contact).
Ascertainment of secondary cases
Secondary infection risks (SIRs) were calculated as the proportion of identified secondary cases divided by the total number of contacts. It should be noted that the crude calculation of SIRs as an overall conditional risk of infection given exposure involves the following assumptions: (i) all the contacts are equally susceptible, and (ii) the SIR is a conditional risk given exposure to the index case(s), and is examined for a reasonable length of time following an illness onset in the index case. Depending on the case definition, SIRs can take different values due to differential efficiency in identifying pH1N1 infection, e.g. by virologic testing, serologic evidence of infection, a rapid detection testing (RDT) result, or by syndromic definition such as influenzalike illness (ILI) symptoms and acute respiratory infection (ARI). Laboratory methods to confirm pH1N1 infections included the reverse transcription PCR (RTPCR) or viral culture on specimens collected from the respiratory tract. Serologic methods included an analysis of paired serological specimens by hemagglutination inhibition or microneutralization assays, with a 4fold or greater rise between baseline and convalescent period conventionally used to indicate an infection. ILI was frequently defined as the presence of fever plus cough or sore throat, i.e., a common surveillance definition of the influenzalike illness. Some studies also reported the occurrence of ARI among contacts where ARI was defined as febrile or afebrile upper respiratory tract infection, commonly in the presence of two or more influenzarelated signs or symptoms.
Data extraction
The primary data extracted were the total numbers of contacts and secondary cases per single primary case with prophylaxis, which were commonly compared against the same data among contacts without prophylaxis. If reported, the information with respect to the number of primary cases with incomplete prophylaxis or who dropped out from the prophylaxis was extracted. Other than these aspects, we extracted the information concerning the ascertainment of secondary cases, the specific outbreak setting (e.g. household or school), the antiviral agents that have been used for prophylaxis, the durations of prophylaxis and other countermeasures, the time from illness onset to starting prophylaxis, containment measures other than contact tracing and chemoprophylaxis, any indication of drug resistance (e.g. report of H275Y mutant), and the numbers of cases with pneumonia and deaths. All the datasets were summarized in a standardized form.
Statistical analysis of reviewed SIRs
SIRs were stratified according to the presence and absence of prophylaxis. Statistical heterogeneity was assessed by I ^{2} statistic which represents the extent of the degree of variation. All statistical data were analysed using a statistical software JMP version 9.0.0 (SAS Institute Inc., Cary, NC, USA).
Modelling method
where M _{t} scales the total number of boarders in the beginning of day t (i.e. used for scaling the cumulative incidence).
where k is the dispersion parameter that was estimated jointly with other parameters. Both Poisson and geometric distributions are the special cases of this negative binomial distribution with k → ∞ and k → 0, respectively. Maximum likelihood estimates of the parameters were obtained by minimizing the negative logarithm of the likelihood function (10), (11) or (12). The 95% confidence interval (CI) was computed by using the profile likelihood. To compare model fits, we employed the Akaike’s Information Criterion.
Results
Reviewed literature
Studies on contact tracing and antiviral prophylaxis against influenza A (H1N12009) included in the systematic review
Authors  Country  Year  Outbreak Setting  Index case ascertainment  No. index cases  No. subjects traced  Postexposure prophylaxis  Dose and duration 

Baz et al. [18]  Canada  2009  Household  RTPCR  1  4  oseltamivir  10 days 
Calatayud et al. [19]  United Kingdom  2009  School  RTPCR  23  2042  oseltamivir  N/A 
CDC [20]  Colorado, USA  2009  Long Term Care Facilities  ILI  21  43  oseltamivir  N/A 
CDC [20]  Maine, USA  2009  Long Term Care Facilities  ILI/RTPCR  9  284  oseltamivir  14 days 
CDC [20]  New York City, USA  2009  Long Term Care Facilities  RTPCR  1  983  oseltamivir  N/A 
Fallo et al. [21]  Argentina.  2009  Household  RTPCR  92  266  oseltamivir  N/A 
France et al. [22]  USA  2009  School (High School)/Household  ILI/RTPCR  222  50  oseltamivir (n = 46), zanamivir (n = 4)  N/A 
Iioka et al. [23]  Japan  2010  Hospital ward  RDT  1  49  oseltamivir  N/A 
Jackson et al. [24]  USA  2009  Household  RTPCR/Serology  32  9.7^{†}  oseltamivir  N/A 
Komiya et al. [6]  Japan  2009  Household  RTPCR  124  333  oseltamivir (n = 232), zanamivir (n = 63) & others (n = 38)  7–10 days 
Kute et al. [25]  India  2010  Hospital ward  RTPCR  1  1  oseltamivir  10 days 
Leung et al. [26]  Hong Kong  2009  School (Secondary school)/Household  RTPCR  65  64  oseltamivir  N/A 
Lisena et al. [27]  Italy  2009  Household  RTPCR  1  5  oseltamivir  10 days 
Maltezou et al. [28]  Greece  2011  Hospital ward  N/A  N/A  13  oseltamivir  10 days 
Morgan et al. [29]  USA  2009  Household  RTPCR  N/A  92  oseltamivir  N/A 
Pannaraj et al. [30]  USA  2009  Hospital ward  ILI/RDT/RTPCR  11  21  oseltamivir  9–10 days 
Tsagris et al. [31]  Greece  2011  Hospital ward  RTPCR  2  20  oseltamivir  10 days 
van Gemert et al. [32]  Australia  2009  Household  RTPCR  N/A  57  oseltamivir  N/A 
Weston et al. [33]  Australia  2009  School (Primary School)  Not specified  1  83  oseltamivir  N/A 
Secondary infection risks (SIR) during contact tracing and chemoprophylaxis against influenza A (H1N12009)
Authors  Ages traced  No. subjects traced  Secondary cases with prophylaxis  SIR % (95% CI) with prophylaxis  No. w/o prophylaxis  Secondary cases w/o prophylaxis  SIR % (95% CI) w/o prophylaxis  Secondary case ascertainment 

Baz et al. [18]  15, 18, 50 and 59 y/o  4  1  25.0 (0, 67.4)  0  0  NC  RTPCR 
Calatayud et al. [19]  N/A  2042  0  0  N/A  N/A  N/A  RTPCR 
CDC [20]  N/A  43  0  0  N/A  N/A  N/A  ILI 
CDC [20]  N/A  284  6  2.1 (0.4, 3.8)  16  0  0  ILI 
CDC [20]  N/A  983  176  17.9 (15.5, 20.3)  N/A  N/A  N/A  ILI 
Fallo et al. [21]  N/A  266  29  10.9 (7.2, 14.7)  31  12  38.7 (21.6, 55.9)  ARI/ILI 
France et al. [22]  Median 45 y/o (range: 0–91 y/o)  50  2  4.0 (0, 9.4)  651  76  11.7 (9.2, 14.1)  ILI 
Iioka et al. [23]  N/A  49  6  12.2 (3.1, 21.4)  0  0  NC  RDT/RTPCR 
Jackson et al. [24]  N/A  9.7^{†}  3.6^{†}  37.1 (6.7, 67.5)  69.3^{†}  11.5^{†}  16.6 (7.8, 25.4)  Serology 
Komiya et al. [6]  Median 43 y/o (quartiles: 0–82)  333  2  0.6 (0, 1.4)  46  12  26.1 (13.4, 38.8)  RTPCR 
Kute et al. [25]  40 y/o  1  0  0  0  0  NC  ILI 
Leung et al. [26]  N/A  64  0  0  141  12  8.5 (3.9, 13.1)  RTPCR 
Lisena et al. [27]  Not specified  5  0  0  1  1  100 (NC)  RTPCR 
Maltezou et al. [28]  Median 11 days (0–27 days)  13  0  0  0  0  NC  ILI 
Morgan et al. [29]  N/A  92  18  19.6 (11.5, 27.7)  143  12  8.4 (3.8, 12.9)  ARI/ILI/RTPCR 
Pannaraj et al. [30]  2–343 d/o  21  0  0  0  0  NC  ILI 
Tsagris et al. [31]  Below 1 y/o  20  1  5.0 (0, 14.6)  0  0  NC  RTPCR 
van Gemert et al. [32]  1–74 y/o  57  1  1.8 (0, 5.2)  65  17  26.2 (15.5, 36.8)  ILI 
Weston et al. [33]  N/A  83  2  2.4 (0, 5.7)  0  0  NC  Non Specified 
Secondary infection risks (SIR) of influenza A (H1N12009) in relation to the timing of prophylaxis, containment measures and other factors
Authors  SIR % (95% CI) with prophylaxis  Time to start prophylaxis  Containment measures other than contact tracing and chemoprophylaxis  Report of H275Y mutant  No. of cases with pneumonia  No. of deaths 

Baz et al. [18]  25.0 (0, 67.4)  0–2 days  N/A  Yes  N/A  N/A 
Calatayud et al. [19]  0  0–10 days  School closure  No  N/A  N/A 
CDC [20]  0  0–4 days  Movement to care unit  No  0  0 
CDC [20]  2.1 (0.4, 3.8)  N/A  Movement restriction, Facility closure to new admission and visitors  No  N/A  N/A 
CDC [20]  17.9 (15.5, 20.3)  within 24 hours  Restriction of visiting  No  N/A  N/A 
Fallo et al. [21]  10.9 (7.2, 14.7)  N/A  N/A  No  N/A  N/A 
France et al. [22]  4.0 (0, 9.4)  N/A  N/A  No  N/A  N/A 
Iioka et al. [23]  12.2 (3.1, 21.4)  immediately after illness onset in index case  Refusal of new admission, Entry restriction  Yes  3 (50%)  3 (50%) 
Jackson et al. [24]  37.1 (6.7, 67.5)  N/A  N/A  No  N/A  N/A 
Komiya et al. [6]  0.6 (0, 1.4)  median 2 days (quartiles: 0–7)  Staying at home  Yes  N/A  N/A 
Kute et al. [25]  0  N/A  N/A  No  0  0 
Leung et al. [26]  0  N/A  School closure  No  0  0 
Lisena et al. [27]  0  1–2 days  N/A  No  0  0 
Maltezou et al. [28]  0  N/A  N/A  No  0  0 
Morgan et al. [29]  19.6 (11.5, 27.7)  N/A  N/A  No  N/A  N/A 
Pannaraj et al. [30]  0  N/A  N/A  No  0  0 
Tsagris et al. [31]  5.0 (0, 14.5)  N/A  N/A  No  1 (100%)  0 (0%) 
van Gemert et al. [32]  1.8 (0, 5.2)  median 6 days  Separation and restriction of movement in their homes  No  N/A  N/A 
Weston et al. [33]  2.4 (0, 5.7)  1–2 days  Quarantine  No  N/A  N/A 
With respect to index case ascertainment (Table 1), RTPCR was used in 15 outbreaks (78.9%), ILI was adopted in 4 (21.1%) and RDT was used in 2 outbreaks (10.5%), respectively. The numbers of index cases and traced contacts were reported in 16 of 19 (84.2%) and 19 of 19 outbreaks (100%), respectively. The median numbers of index cases and contacts per study were 10.0 (quartile: 1.0, 56.8) and 50.0 (quartile: 13.0, 266.0), respectively. The median number of contacts per index case was calculated at 3.4 (quartile: 1.2, 44.6). As for prophylaxis, 17 outbreaks (89.5%) employed oseltamivir alone. Of the total of 19 outbreaks, 5 (26.3%) outbreaks reported that the duration of prophylaxis was set at 10 days for oseltamivir alone and 7–10 days for a combination of oseltamivir and zanamivir. The different regimens of 9–10 days and 14 days for oseltamivir alone were adopted in 1 (5.3%) outbreak for each.
Secondary infection risk and prophylaxis
Median SIRs among exposed individuals with and without prophylaxis were estimated at 2.1% (quartile: 0, 12.2) and 16.6% (quartile: 8.4, 32.4), respectively (Table 2). I ^{2} statistic was calculated at 71.8%. Of the 19 outbreaks, only 8 outbreaks (42.1%) reported SIRs for both of those with and without prophylaxis. Employing a paired ttest with n = 8, the SIR among prophylaxis group appeared to be only marginally significantly smaller than that among the control group (p = 0.052). In two studies, the SIRs among those without prophylaxis were smaller than the SIRs among those with prophylaxis, and the underlying reason for this finding was not manually identifiable. SIR among those who undertook prophylaxis was not significantly associated with the number of traced contacts (p = 0.75, a linear regression). Combining the outbreak setting information in Table 1 with those in Table 2, we found that median SIR with prophylaxis at school setting was 1.2% (quartile: 0, 3.6), being smaller than that at nonschool settings with 2.1% (quartile: 0, 17.9) (Welch ANOVA, p = 0.03). Outbreaks occurring in households did not yield significantly higher SIR than other settings (p = 0.12, ttest). When we stratify the SIR by ascertainment method (i.e. syndromic or laboratory diagnosis), median SIR with prophylaxis ascertained by ILI was 1.9% (quartile: 0, 12.7), which was slightly smaller than those based on RTPCR with the median SIR of 2.4% (quartile: 0, 18.6). No significant association was identified between SIR and the ascertainment method (p = 0.50, ttest).
The median length of delay from exposure to prophylaxis was 1.5 days (quartile: 0.8, 2.5), which was not associated with SIR (p = 0.14, linear regression; Table 3). Median SIR in outbreaks with clearly documented additional countermeasures (e.g. school closure) was 1.8% (quartile: 0, 7.3) which was smaller than other studies with median SIR of 4.5% (quartile: 0, 20.9). However, the difference was not significantly different (p = 0.21, ttest). Outbreaks with a report of mutation marker of resistance yielded greater SIR (median 12.2% (quartile: 0.6, 25.0)) as compared to those without any report of resistance (median 1.9% (quartile: 0, 9.4)), but the difference was not significant (p = 0.47, ttest). A total of eight studies explicitly documented the numbers of cases with pneumonia and fatal outcome (Table 3). Of these, 1 study reported three deaths due to pneumonia and another study reported one pneumonia case who had eventually recovered.
Description of the outbreak in Madagascar
Modelling results
Estimates for the parameters governing the transmission dynamics of influenza A (H1N12009) in a primary school in Madagascar, 2009
Offspring distribution  Depletion of susceptibles  Reproduction number (95% CI ^{‡})  % Reduction in transmissibility by treatment (95% CI ^{‡})  % Reduction in transmissibility by contact tracing and chemoprophylaxis (95% CI ^{‡})  % Reduction in transmissibility by school closure (95% CI ^{‡})  AIC ^{§} 

Poisson  Yes  4.8 (1.8, 9.6)  14.1 (0, 72.1)  94.3 (87.6, 97.7)  31.6 (0, 76.8)  37.9 
Poisson  No  6.0 (2.2,12.2)  4.4 (0, 68.2)  93.3 (85.6, 97.3)  10.0 (0, 69.5)  35.0 
Geometric  Yes  6.6 (1.5, NC)  26.1 (0, NC)  94.1 (71.8, 98.7)  40.6 (0, NC)  39.7 
Geometric  No  7.4 (1.6, NC)  12.8 (NC, NC)  92.8 (66.7, 98.4)  15.1 (0, NC)  39.1 
Negative binomial  Yes  6.6 (2.2, 16.4)  27.7 (0, 85.5)  95.4 (87.7, 98.4)  48.0 (0, 84.8)  37.6 
Negative binomial  No  7.2 (2.5, 17.0)  13.1 (0, 78.4)  94.0 (85.6, 97.8)  22.6 (0, 76.2)  36.1 
Table 4 summarizes the parameter estimates of the proposed model and the effectiveness of prophylaxis, treatment and school closure. The effectiveness of mass chemoprophylaxis ranged from 92.8% to 95.4% according to different model assumptions and likelihood functions. The estimated high values should be cautiously interpreted as they do not only represent the effect of antiviral prophylaxis but also many other factors that could arise from rigorous contact tracing. The estimated effectiveness of antiviral prophylaxis was less sensitive to the incorporation of the depletion of susceptible individuals and the choice of likelihood function, especially when it was compared with the sensitivities of other parameters including the reproduction number (the MLE ranging from 4.8 to 7.4), the effectiveness of antiviral treatment (the MLE from 4.4% to 26.1%) and the effectiveness of school closure (the MLE ranging from 10.0% to 48.0%). In other words, Table 4 suggests that the effectiveness of chemoprophylaxis coupled with contact tracing that is greater than 92% is a robust finding. With regard to the model fit, the simplest type, i.e., a Poisson distributed likelihood without depletion of susceptibles, yielded the minimum AIC value (35.0).
Figure 3B shows the estimate of the effective reproduction number along with the 95% confidence interval based on a model that explicitly accounted for the depletion of susceptible individuals. Here the effective reproduction number represents the average number of secondary cases per primary case at calendar time t in the absence of any interventions. Both the expected value and the lower 95% confidence limit were continuously above unity, indicating that the outbreak could have lasted for a longer time if no intervention took place. In other words, the outbreak was likely to have declined to extinction due to concerted interventions.
Discussion
The present study explored published literature on antiviral prophylaxis and contact tracing against pH1N1, aiming to systematically investigate the published data and explicitly estimate the effectiveness using a modelling approach that has been already used for exploring various aspects of contact tracing [34–36]. In the systematic review, a very high heterogeneity in the SIR was identified, which was likely associated with differential settings of exposure and nonuniform designs of observational studies. Although the SIR among those who undertook the prophylaxis was significantly smaller than the control group, it appeared infeasible to explicitly estimate the effectiveness of prophylaxis in reducing the transmission of influenza based on a simple metaanalysis of retrospective observational studies. As a supplementary approach, we have devised a mathematical model, applying it to a single particular outbreak in Madagascar and yielding the estimates of the effectiveness of prophylaxis and other countermeasures. A renewal equation model, which has attracted scientific interest in other recent applications [37], was employed. The effectiveness of prophylaxis coupled with contact tracing was estimated as high as 92% or greater, which appeared to be robust to differential model assumptions. This was also in good agreement with the relative reduction in median SIR by prophylaxis, calculated at 87.3%. A mathematical modelling exercise focusing on a specific dataset satisfied the need to explicitly estimate the effectiveness.
There has been a published systematic review of randomized controlled trials (RCT) on the effectiveness of antiviral prophylaxis at an individual level [8]. However, the exposure in the controlled trials has had to be very specific and comparable across studies, and thus, the result has not been directly applicable to a variety of practical settings (e.g. for policymaking at a population level). In fact, there has not been a generally accepted mathematical procedure in translating the individual estimate during a certain contact into the likely effectiveness at a population level (e.g. in a school). This indicates that the population benefit of implementing prophylaxis as part of containment measures has remained unclear even after the RCT. In such an instance, we believe that it is useful to estimate the effectiveness from retrospectively collected data at population levels, even though observational study design is vulnerable to various factors including case ascertainment and indirect impact of contact tracing on the spread of disease. We systematically searched for all potentially available literature, although there was only the limited available information with a difficulty in disentangling the datagenerating process. Our review identified that different studies employed different methods of “ascertainment” and different definitions of “exposure”, not allowing us to conduct a simple and explicit metaanalysis. On the other hand, modelling analysis offered a robust estimate of the effectiveness of prophylaxis, demonstrating that the contact tracing with prophylaxis yielded an apparent reduction in the risk of secondary transmission. This finding unfortunately applies only to the specific school setting in Madagascar, but our study adds to literature including studies among military conscripts in Singapore, supporting the notion that it is worth considering the containment measure with antiviral prophylaxis.
An important data gap should be identified for future observational studies, because an explicit statistical analysis could be made based on a welldesigned observational study [38]. The designed observational study could also satisfy other objectives including the determination of optimal duration of prophylaxis [39]. As we discussed earlier, one particular study setting offers the estimate that is applicable to only the same setting, preventing us from offering a broadly applicable finding to other populations. However, considering that our modelling exercise successfully estimated the effectiveness of antiviral prophylaxis for a particular outbreak at a school setting, and given that it is difficult to disentangle the relationship between individual effect in RCTs and its relevance to the effectiveness at a confined setting, future study should collect the dataset in a particular confined setting with the details of exposure information (e.g. the time from exposure to prophylaxis and the extent/density of the contact) adopting common methodology for ascertainment and exposure across different studies. One could subsequently employ a mathematical model to analyse the metadata by combining different datasets of an identical confined setting (e.g. metadata of school outbreaks). As long as we can ensure the comparability of ascertainment method and contact across different studies during the systematic review, the analysis of metadata using mathematical modelling techniques could possibly yield more or less comparable and widely applicable results. In fact, a recent modelling study analysed the metadata of household transmission studies, estimating a key parameter that governs the transmissibility as well as identifying the extent of heterogeneity [40]. Unfortunately, the presently available data on chemoprophylaxis (Table 1) did not permit us to conduct a similar modelbased metaanalysis due mainly to inconsistency of the definition of contact and shortage of information. However, future studies can systematically address the abovementioned points by focusing on a specific confined setting such as household or school.
Three technical limitations should be noted. First, our systematic review investigated retrospective observational studies that did not provide us with sufficient epidemiological information and sample size. Because of different outbreak settings with missing data, we did not adhere to formal methodology of metaanalysis and, for instance, did not account for the weight of each study based on sample size when implementing any hypothesis testing. A more controlled analytical method with an identical exposure setting and greater sample size could offer some positive important finding in the future. Second, the outbreak in Madagascar occurred in a school setting and we applied a homogeneously mixing model to the data. The validity of applying such an approximate model to close contact data has yet to be assessed. An explicit validation including the appropriateness of computing the threshold quantity is called for. Moreover, one should remember that our modelling approach ignored asymptomatically infected individuals who could have been infectious to others. Third, the generation time was assumed as known. Although one could try to estimate the generation time jointly with other parameters from epidemic data, the generation time distribution of the small outbreak data should be far from the stable distribution [16] and the timedependency in a specific population (e.g. boarders) which is likely to form clusters is expected to be complex [41, 42].
Despite a need for improvements in a number of different methodological aspects to explicitly assess the feasibility of antiviral prophylaxis as part of containment measure, the present study at least identified the associated epidemiological data gaps. When an outbreak is confined to a particular setting, we have shown that one can use the time of illness onset and the detailed timing of interventions to estimate the effectiveness of prophylaxis by employing a mathematical model. As long as we improve the study designs including common methodologies of ascertainment and contact tracing, mathematical modelling will be a very useful tool to analyse the metadata and answer pressing public health questions [43].
Conclusions
The present study systematically reviewed retrospective studies that explored the effectiveness of antiviral prophylaxis during the 2009 pandemic and explicitly estimated the effectiveness by employing a mathematical model. In the systematic review, a very high heterogeneity in the SIR was identified with I ^{2} statistic at 71.8%. It was difficult to explicitly estimate the effectiveness of prophylaxis based on simple metaanalysis of retrospective observational studies. However, modelling analysis of a single outbreak successfully yielded an estimate of the effectiveness, ranging from 92.8% to 95.4% according to different model assumptions and likelihood functions. Future studies could fill the data gap in retrospective observational studies including the investigation of cases and contacts and analyse the metadata using a mathematical model.
Declarations
Acknowledgements
HN received funding support from the Japan Science and Technology Agency (JST) PRESTO program and St Luke’s Life Science Institute Research Grant for Clinical Epidemiology Research 2012. This work also received financial support from the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558) and the Area of Excellence Scheme of the Hong Kong University Grants Committee (Grant no. AoE/M12/06). The funding bodies were not involved in the collection, analysis and interpretation of data, the writing of the manuscript or the decision to submit for publication.
Authors’ Affiliations
References
 Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson NM, Rambaut A, Pybus OG, LopezGatell H, AlpucheAranda CM, Chapela IB, Zavala EP, Guevara DM, Checchi F, Garcia E, Hugonnet S, Roth C, WHO Rapid Pandemic Assessment Collaboration: Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009, 324: 15571561. 10.1126/science.1176062.PubMed CentralView ArticlePubMedGoogle Scholar
 Nishiura H: Case fatality ratio of pandemic influenza. Lancet Infect Dis. 2010, 10: 443444. 10.1016/S14733099(10)701201.View ArticlePubMedGoogle Scholar
 Viboud C, Miller M, Olson D, Osterholm M, Simonsen L: Preliminary estimates of mortality and years of life lost associated with the 2009 a/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr. 2010, 2: RRN1153PubMed CentralView ArticlePubMedGoogle Scholar
 Wu P, Cowling BJ, Wu JT, Lau EH, Ip DK, Nishiura H: The epidemiological and public health research response to 2009 pandemic influenza A(H1N1): experiences from Hong Kong. Influenza Other Respi Viruses. 2012, 10.1111/j.17502659.2012.00420.x. in pressGoogle Scholar
 Odaira F, Takahashi H, Toyokawa T, Tsuchihashi Y, Kodama T, Yahata Y, Sunagawa T, Taniguchi K, Okabe N: Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A(H1N1)v outbreak in Kobe, Japan, MayJune 2009. Euro Surveill. 2009, 14: pii=19320Google Scholar
 Komiya N, Gu Y, Kamiya H, Yahata Y, Yasui Y, Taniguchi K, Okabe N: Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009. J Infect. 2010, 61: 284288. 10.1016/j.jinf.2010.06.019.View ArticlePubMedGoogle Scholar
 Lau LL, Nishiura H, Kelly H, Ip DK, Leung GM, Cowling BJ: Household transmission of 2009 pandemic influenza A (H1N1): a systematic review and metaanalysis. Epidemiology. 2012, 23: 531542. 10.1097/EDE.0b013e31825588b8.PubMed CentralView ArticlePubMedGoogle Scholar
 Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK: Systematic review: safety and efficacy of extendedduration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med. 2009, 151: 464473.View ArticlePubMedGoogle Scholar
 Lee VJ, Yap J, Cook AR, Chen MI, Tay JK, Tan BH, Loh JP, Chew SW, Koh WH, Lin R, Cui L, Lee CW, Sung WK, Wong CW, Hibberd ML, Kang WL, Seet B, Tambyah PA: Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N Engl J Med. 2010, 362: 21662174. 10.1056/NEJMoa0908482.View ArticlePubMedGoogle Scholar
 Lee VJ, Yap J, Tay JK, Barr I, Gao Q, Ho HJ, Tan BH, Kelly PM, Tambyah PA, Kelso A, Chen MI: Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009. BMC Infect Dis. 2010, 10: 16410.1186/1471233410164.PubMed CentralView ArticlePubMedGoogle Scholar
 Lee VJ, Yap J, MaurerStroh S, Lee RT, Eisenhaber F, Tay JK, Ting PJ, Loh JP, Wong CW, Tan BH, Koay ES, Kelly PM, Hibberd ML: Investigation of causes of oseltamivir chemoprophylaxis failures during influenza A (H1N12009) outbreaks. J Clin Virol. 2011, 50: 104108. 10.1016/j.jcv.2010.10.004.View ArticlePubMedGoogle Scholar
 Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009, 6: e100009710.1371/journal.pmed.1000097.PubMed CentralView ArticlePubMedGoogle Scholar
 Rajatonirina S, Heraud JM, Randrianasolo L, Razanajatovo N, Ramandimbisoa T, Ratsitorahina M, Richard V: Pandemic influenza A(H1N1) 2009 virus outbreak among boarding school pupils in Madagascar: compliance and adverse effects of prophylactic oseltamivir treatment. J Infect Dev Ctries. 2011, 5: 156162.PubMedGoogle Scholar
 Ejima K, Omori R, Aihara K, Nishiura H: Realtime investigation of measles epidemics with estimate of vaccine efficacy. Int J Biol Sci. 2012, 8: 620629. 10.7150/ijbs.4329.PubMed CentralView ArticlePubMedGoogle Scholar
 Ejima K, Omori R, Cowling BJ, Aihara K, Nishiura H: The time required to estimate the case fatality ratio of influenza using only the tip of an iceberg: joint estimation of the virulence and the transmission potential. Comput Math Methods Med. 2012, 2012: e978901View ArticleGoogle Scholar
 Roberts MG, Nishiura H: Early estimation of the reproduction number in the presence of imported cases: pandemic influenza H1N12009 in New Zealand. PLoS One. 2011, 6: e1783510.1371/journal.pone.0017835.PubMed CentralView ArticlePubMedGoogle Scholar
 Becker N: On parametric estimation for mortal branching processes. Biometrika. 1974, 61: 393399.View ArticleGoogle Scholar
 Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G: Emergence of oseltamivirresistant pandemic H1N1 virus during prophylaxis. N Engl J Med. 2009, 361: 22962297. 10.1056/NEJMc0910060.View ArticlePubMedGoogle Scholar
 Calatayud L, Kurkela S, Neave PE, Brock A, Perkins S, Zuckerman M, Sudhanva M, Bermingham A, Ellis J, Pebody R, Catchpole M, Heathcock R, Maguire H: Pandemic (H1N1) 2009 virus outbreak in a school in London, AprilMay 2009: an observational study. Epidemiol Infect. 2010, 138: 183191. 10.1017/S0950268809991191.View ArticlePubMedGoogle Scholar
 Centers for Disease Control and Prevention (CDC): Outbreaks of 2009 pandemic influenza A (H1N1) among longtermcare facility residents  three states, 2009. MMWR Morb Mortal Wkly Rep. 2010, 59: 7477.Google Scholar
 Fallo AA, Contrini MM, Neyro S, López EL: Case characteristics and use of oseltamivir in children and household contacts. Pediatr Infect Dis J. 2012, 31: 781783. 10.1097/INF.0b013e318256c06b.View ArticlePubMedGoogle Scholar
 Iioka F, Sada R, Maesako Y, Nakamura F, Ohno H: Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation. Int J Hematol. 2012, 96: 364369. 10.1007/s1218501211391.View ArticlePubMedGoogle Scholar
 France AM, Jackson M, Schrag S, Lynch M, Zimmerman C, Biggerstaff M, Hadler J: Household transmission of 2009 influenza A (H1N1) virus after a schoolbased outbreak in New York City, AprilMay 2009. J Infect Dis. 2010, 201: 984992. 10.1086/651145.View ArticlePubMedGoogle Scholar
 Jackson ML, France AM, Hancock K, Lu X, Veguilla V, Sun H, Liu F, Hadler J, Harcourt BH, Esposito DH, Zimmerman CM, Katz JM, Fry AM, Schrag SJ: Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave–New York City, AprilMay 2009. Clin Infect Dis. 2011, 53: 455462. 10.1093/cid/cir437.View ArticlePubMedGoogle Scholar
 Kute V, Goplani KR, Godara SM, Shah PR, Vanikar AV, Trivedii HL: Postexposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient–safe and effective without any immunosuppresive drug interaction. J Assoc Physicians India. 2011, 59: 4951.PubMedGoogle Scholar
 Leung YH, Li MP, Chuang SK: A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. Epidemiol Infect. 2011, 139: 4144. 10.1017/S0950268810001445.View ArticlePubMedGoogle Scholar
 Lisena F, Bordi L, Carletti F, Castilletti C, Ferraro F, Lalle E, Lanini S, Ruscitti LE, Fusco FM: Influenza A (H1N1) in Rome. Italy in family: three case reports. Cases J. 2009, 2: 912310.1186/1757162629123.PubMed CentralView ArticlePubMedGoogle Scholar
 Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, Dotsikas Y, Loukas YL, Theodoridou M: Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1. Pediatr Infect Dis J. 2012, 31: 527529. 10.1097/INF.0b013e3182472f28.View ArticlePubMedGoogle Scholar
 Morgan OW, Parks S, Shim T, Blevins PA, Lucas PM, Sanchez R, Walea N, Loustalot F, Duffy MR, Shim MJ, Guerra S, Guerra F, Mills G, Verani J, Alsip B, Lindstrom S, Shu B, Emery S, Cohen AL, Menon M, Fry AM, Dawood F, Fonseca VP, Olsen SJ: Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, AprilMay 2009. Emerg Infect Dis. 2010, 16: 631637. 10.3201/eid1604.091658.PubMed CentralView ArticlePubMedGoogle Scholar
 Pannaraj PS, Tam B, Akan D: Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol. 2011, 31: 487493. 10.1038/jp.2010.159.View ArticlePubMedGoogle Scholar
 Tsagris V, Nika A, Kyriakou D, Kapetanakis I, Harahousou E, Stripeli F, Maltezou H, Tsolia M: Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit. J Hosp Infect. 2012, 81: 3640. 10.1016/j.jhin.2012.02.009.View ArticlePubMedGoogle Scholar
 van Gemert C, Hellard M, McBryde ES, Fielding J, Spelman T, Higgins N, Lester R, Vally H, Bergeri I: Intrahousehold transmission of pandemic (H1N1) 2009 virus, Victoria Australia. Emerg Infect Dis. 2011, 17: 15991607. 10.3201/eid1709.101948.PubMed CentralView ArticlePubMedGoogle Scholar
 Weston KM, Truman G: An influenza prophylaxis clinic in a primary school: 24 hours from notification to protection. N S W Public Health Bull. 2010, 21: 1618. 10.1071/NB09032.View ArticlePubMedGoogle Scholar
 Moghadas SM, Bowman CS, Röst G, Fisman DN, Wu J: Postexposure prophylaxis during pandemic outbreaks. BMC Med. 2009, 7: 7310.1186/17417015773.PubMed CentralView ArticlePubMedGoogle Scholar
 Armbruster B, Brandeau ML: Contact tracing to control infectious disease: when enough is enough. Health Care Manag Sci. 2007, 10: 341355. 10.1007/s1072900790276.PubMed CentralView ArticlePubMedGoogle Scholar
 Armbruster B, Helleringer S, KalilaniPhiri L, Mkandawire J, Kohler HP: Exploring the relative costs of contact tracing for increasing HIV case finding in subSaharan countries. J Acquir Immune Defic Syndr. 2011, 58: e29e36. 10.1097/QAI.0b013e31822a9fa8.PubMed CentralView ArticlePubMedGoogle Scholar
 Mahiane GS, Ouifki R, Brand H, Delva W, Welte A: A general HIV incidence inference scheme based on likelihood of individual level data and a population renewal equation. PLoS One. 2012, 7: e4437710.1371/journal.pone.0044377.PubMed CentralView ArticlePubMedGoogle Scholar
 Yang Y, Longini IM, Halloran ME: Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. Appl Stat. 2006, 55: 317330.Google Scholar
 Brookmeyer R, Johnson E, Bollinger R: Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci USA. 2003, 100: 1012910132. 10.1073/pnas.1631983100.PubMed CentralView ArticlePubMedGoogle Scholar
 House T, Inglis N, Ross JV, Wilson F, Suleman S, Edeghere O, Smith G, Olowokure B, Keeling MJ: Estimation of outbreak severity and transmissibility: Influenza A(H1N1)pdm09 in households. BMC Med. 2012, 10: 11710.1186/1741701510117.PubMed CentralView ArticlePubMedGoogle Scholar
 Nishiura H: Time variations in the generation time of an infectious disease: implications for sampling to appropriately quantify transmission potential. Math Biosci Eng. 2010, 7: 851869.View ArticlePubMedGoogle Scholar
 Oei W, Nishiura H: The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918–19. Comput Math Methods Med. 2012, 2012: 124861PubMed CentralView ArticlePubMedGoogle Scholar
 Chowell G, Nishiura H: Toward unbiased assessment of treatment and prevention: modeling household transmission of pandemic influenza. BMC Med. 2012, 10: 11810.1186/1741701510118.PubMed CentralView ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.